Top Markets
#1 Black Phoenix Black Phoenix +21,321.25%
#2 Nesa Nesa +767.20%
#3 Cortex Cortex +67.67%
#4 Kinesis Silver Kinesis Silver +55.16%
#5 Derive Derive +24.28%
#6 QuantixAI QuantixAI +23.76%
#7 EXOD EXOD +22.78%
#8 Cash Cat Cash Cat +16.11%
#9 Bless Bless +14.01%
#10 Pons Pons +13.84%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Cypherpunk Technologies Inc. Cypherpunk Technologies Inc.

Cypherpunk Technologies Inc.

CYPH
Rank in Stocks #19170
Cypherpunk Technologies Inc. is a biopharmaceutical company dedicated to the... Cypherpunk Technologies Inc. is a biopharmaceutical company dedicated to the acquisition and development of antibody treatments for cancer. The firm's flagship investigational drug, DKN-01, is a monoclonal antibody designed to suppress Dickkopf-related protein 1 and is currently progressing through multiple clinical trials for various esophagogastric, gynecologic, and colorectal cancers. Additionally, the company is advancing FL-501, another monoclonal antibody that targets the GDF-15 protein, which is presently in preclinical development. Cypherpunk has established an agreement with Adimab, LLC and BeiGene, Ltd., granting it options and licenses to advance and market DKN-01 across Asia (excluding Japan), Australia, and New Zealand. Founded in 2011, the company operates from Cambridge, Massachusetts, and was formerly known as Leap Therapeutics, Inc. until its renaming in November 2025.
Share Price
$1.62
Last synced: 2026-08-25
Market Cap
$172.47M
Change (1 day)
-3.57%
Change (1 year)
446.74%
Country
US
Trade Cypherpunk Technologies Inc. (CYPH)

Category

Healthcare
Revenue for Cypherpunk Technologies Inc. (CYPH)
Revenue in Aug 2026 TTM: 0
According to Cypherpunk Technologies Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Cypherpunk Technologies Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH